FDA warns of HIV drug mix-up

Apr 12, 2007

The U.S. Food and Drug Administration said Thursday that bottles of HIV drug Ziagen may have been mislabeled as Combivir, another HIV drug.

The FDA and GlaxoSmithKline, which makes both drugs, said it appears the bottles were tampered with by a third party that used counterfeit labels to mislead readers about the contents, WebMD reported Thursday.

GlaxoSmithKline said in a letter to pharmacists that no injuries have been reported from the tampering. However, Ziagen's active ingredient may cause hypersensitivity reactions in some patients that could be life threatening.

"These incidents appear to be isolated and limited in scope to one pharmacy in California," the FDA said.

The labels on the tampered bottles were identified as Lot No. 6ZP9760 with expiration dates of April 2010 and April 2009.

Combivir tablets are white and have "GX FC3" engraved on one side, while Ziagen tablets are yellow and read "GX 623" on one side.

Copyright 2007 by United Press International

Explore further: Point-of-care CD4 testing is economically feasible for HIV care in resource-limited areas

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

The genetics of coping with HIV

Sep 16, 2014

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

User comments : 0